MX2017000399A - Tableta dispersable de misoprostol. - Google Patents
Tableta dispersable de misoprostol.Info
- Publication number
- MX2017000399A MX2017000399A MX2017000399A MX2017000399A MX2017000399A MX 2017000399 A MX2017000399 A MX 2017000399A MX 2017000399 A MX2017000399 A MX 2017000399A MX 2017000399 A MX2017000399 A MX 2017000399A MX 2017000399 A MX2017000399 A MX 2017000399A
- Authority
- MX
- Mexico
- Prior art keywords
- misoprostol
- dispersible tablet
- pharmaceutically acceptable
- acceptable salt
- relates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Reproductive Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Pregnancy & Childbirth (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invención se relaciona con una formulación farmacéutica sólida que comprende misoprostol o una sal farmacéuticamente aceptable del mismo. En particular, la invención se relaciona con una tableta dispersable que comprende misoprostol o una sal farmacéuticamente aceptable del mismo, proporcionando rutas alternativas de administración. La tableta es particularmente adecuada para maduración cervical, inducción del parto, prevención y/o tratamiento de hemorragia pos-parto o de pos-aborto.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14176821.8A EP2965750B1 (en) | 2014-07-11 | 2014-07-11 | Misoprostol dispersible tablet |
US14/329,023 US20160008310A1 (en) | 2014-07-11 | 2014-07-11 | Misoprostol dispersible tablet |
PCT/DK2015/050216 WO2016004960A2 (en) | 2014-07-11 | 2015-07-10 | Misoprostol dispersible tablet |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017000399A true MX2017000399A (es) | 2017-08-10 |
Family
ID=53879283
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017000399A MX2017000399A (es) | 2014-07-11 | 2015-07-10 | Tableta dispersable de misoprostol. |
Country Status (12)
Country | Link |
---|---|
US (2) | US11406615B2 (es) |
EP (1) | EP3166597A2 (es) |
JP (2) | JP6532529B2 (es) |
AU (1) | AU2015287186B2 (es) |
BR (1) | BR112017000529A2 (es) |
CA (1) | CA2954086C (es) |
EA (1) | EA039069B1 (es) |
MX (1) | MX2017000399A (es) |
NZ (1) | NZ727876A (es) |
RU (1) | RU2017104233A (es) |
TN (1) | TN2017000003A1 (es) |
WO (1) | WO2016004960A2 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108434110B (zh) * | 2018-04-28 | 2019-09-10 | 浙江仙琚制药股份有限公司 | 米索前列醇组合物、片剂及其用途 |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB994518A (en) | 1962-07-18 | 1965-06-10 | Needle Industries Ltd | Improvements relating to shavers |
US4335097A (en) | 1981-01-15 | 1982-06-15 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. | Stabilized, prostaglandin-containing tablets with controlled rate of solubility, for local use and process for the preparation thereof |
DK0574185T3 (da) | 1992-06-08 | 1998-04-20 | Newpharma International Corp | PGE,-analog |
JPH06199779A (ja) | 1992-06-08 | 1994-07-19 | Newpharma Internatl Corp | トランス−▲δ2▼−15−デオキシ−16−ヒドロキシ−16−メチル−pg▲e1▼のメチルエステル(b−407) |
GB9419566D0 (en) | 1994-09-27 | 1994-11-16 | El Refaey Hazem | Oral prostagladins for the routine management of the third stage of labour |
US5993856A (en) | 1997-01-24 | 1999-11-30 | Femmepharma | Pharmaceutical preparations and methods for their administration |
US6228213B1 (en) | 1997-09-19 | 2001-05-08 | University Of Nebraska-Lincoln | Production of microcrystalline cellulose by reactive extrusion |
US7815937B2 (en) | 1998-10-27 | 2010-10-19 | Biovail Laboratories International Srl | Quick dissolve compositions and tablets based thereon |
WO2001013836A1 (en) | 1999-08-26 | 2001-03-01 | West Virginia University | Cervical agent delivery system |
IL150053A0 (en) * | 1999-12-06 | 2002-12-01 | Mendell Co Inc Edward | Pharmaceutical superdisintegrant |
GB2375303A (en) | 2001-05-11 | 2002-11-13 | Medical Res Council | Method of inducing cervical ripening |
GB0204771D0 (en) * | 2002-02-28 | 2002-04-17 | Phoqus Ltd | Fast disintegrating tablets |
SI21221A (sl) | 2002-06-21 | 2003-12-31 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Hitro razpadljive tablete |
TW200502000A (en) * | 2003-03-28 | 2005-01-16 | Kyowa Hakko Kogyo Kk | Dividing tablet |
WO2006125450A1 (en) | 2005-05-26 | 2006-11-30 | Atef Mohammed Mostafa Darwish | Rectal and vaginal suppositories containing misoprostol |
US20060286172A1 (en) | 2005-06-03 | 2006-12-21 | Anu Mahashabde | Pharmaceutical compositions comprising prostanoid-receptor agonists and methods of making and using the same |
US9198862B2 (en) * | 2005-07-22 | 2015-12-01 | Rubicon Research Private Limited | Dispersible tablet composition |
WO2007035954A2 (en) | 2005-09-23 | 2007-03-29 | Duramed Pharmaceuticals, Inc. | Vaginal tablets comprising misoprostol and methods of making and using the same |
US7799530B2 (en) | 2005-09-23 | 2010-09-21 | Celera Corporation | Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof |
CN1939308A (zh) | 2005-09-28 | 2007-04-04 | 应圣俊 | 一种米索前列醇栓剂 |
EP1987820A1 (en) | 2007-05-04 | 2008-11-05 | Christian Fiala, Ph. D. | Slow release misoprostol for obstetric and/or gynaecological applications |
EP2572705B1 (en) * | 2007-10-01 | 2017-09-13 | Laboratorios Lesvi, S.L. | Orodispersible tablets |
WO2009154810A2 (en) * | 2008-02-25 | 2009-12-23 | Dr. Reddy's Laboratories Ltd. | Delivery systems for multiple active agents |
WO2010036878A1 (en) | 2008-09-26 | 2010-04-01 | The Trustees Of Columbia University In The City Of New York | Use of trpv1 receptor agonists in cervical pain and labor |
WO2010109019A1 (en) | 2009-03-26 | 2010-09-30 | Royal College Of Surgeons In Ireland | Orodispersible tablets |
US20100260825A1 (en) | 2009-04-13 | 2010-10-14 | Nair Madhavan G | Antifolates for the treatment of cardiovascular, inflammatory, neoplastic, autoimmune and related diseases in sublingual dosage units, film strips, or skin patches |
RU2394814C1 (ru) | 2009-05-22 | 2010-07-20 | Учреждение Российской академии наук Институт органической химии Уфимского научного центра РАН | Средство, представляющее собой этиловый эфир (±)-11,15-дидезокси-16-метил-16-гидроксипростагландина e1, проявляющее утеротоническую активность |
EP2579866B1 (en) | 2010-06-11 | 2016-05-18 | Ferring B.V. | Intravaginal administration of misoprostol |
CN102302443B (zh) | 2011-09-21 | 2014-04-23 | 天津市聚星康华医药科技有限公司 | 一种米索前列醇阴道缓释栓剂及其制备方法 |
CN102697746B (zh) * | 2012-06-11 | 2014-03-19 | 广州朗圣药业有限公司 | 一种快速融变的米索前列醇阴道用组合物及其制备方法和应用 |
CN104507482A (zh) | 2012-07-26 | 2015-04-08 | 辉凌公司 | 米索前列醇组合物 |
EP2689781A1 (en) | 2012-07-26 | 2014-01-29 | Ferring B.V. | Misoprostol composition |
EP2689802A1 (en) | 2012-07-26 | 2014-01-29 | Ferring B.V. | Misoprostol formulation |
EP2877182A1 (en) | 2012-07-26 | 2015-06-03 | Ferring B.V. | Misoprostol formulation |
CN102872024B (zh) * | 2012-09-28 | 2015-06-17 | 天津市聚星康华医药科技有限公司 | 口腔内使用的米索前列醇药物组合物 |
CN103040842B (zh) | 2012-12-08 | 2014-11-12 | 浙江圣博康药业有限公司 | 一种前列腺素类药物组合物及其制成的前列腺素类药物栓剂 |
CN103340837B (zh) * | 2013-07-08 | 2018-04-27 | 天津市聚星康华医药科技有限公司 | 一种米索前列醇阴道泡腾片及其制备方法 |
-
2015
- 2015-07-10 JP JP2017521290A patent/JP6532529B2/ja active Active
- 2015-07-10 AU AU2015287186A patent/AU2015287186B2/en active Active
- 2015-07-10 WO PCT/DK2015/050216 patent/WO2016004960A2/en active Application Filing
- 2015-07-10 MX MX2017000399A patent/MX2017000399A/es unknown
- 2015-07-10 BR BR112017000529A patent/BR112017000529A2/pt not_active Application Discontinuation
- 2015-07-10 NZ NZ727876A patent/NZ727876A/en unknown
- 2015-07-10 EP EP15750921.7A patent/EP3166597A2/en active Pending
- 2015-07-10 RU RU2017104233A patent/RU2017104233A/ru not_active Application Discontinuation
- 2015-07-10 TN TN2017000003A patent/TN2017000003A1/en unknown
- 2015-07-10 CA CA2954086A patent/CA2954086C/en active Active
- 2015-07-10 EA EA201692536A patent/EA039069B1/ru unknown
-
2019
- 2019-05-20 JP JP2019094296A patent/JP6921894B2/ja active Active
-
2020
- 2020-05-08 US US16/870,556 patent/US11406615B2/en active Active
-
2022
- 2022-07-11 US US17/861,711 patent/US12005041B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
AU2015287186A1 (en) | 2017-01-19 |
NZ727876A (en) | 2018-05-25 |
RU2017104233A3 (es) | 2018-12-18 |
EA201692536A1 (ru) | 2017-06-30 |
CA2954086C (en) | 2020-03-31 |
EP3166597A2 (en) | 2017-05-17 |
WO2016004960A3 (en) | 2016-03-17 |
RU2017104233A (ru) | 2018-08-13 |
AU2015287186B2 (en) | 2018-05-31 |
BR112017000529A2 (pt) | 2017-11-14 |
US12005041B2 (en) | 2024-06-11 |
US20220347145A1 (en) | 2022-11-03 |
US20210322356A1 (en) | 2021-10-21 |
JP2019147831A (ja) | 2019-09-05 |
WO2016004960A2 (en) | 2016-01-14 |
JP6532529B2 (ja) | 2019-06-19 |
US11406615B2 (en) | 2022-08-09 |
CA2954086A1 (en) | 2016-01-14 |
TN2017000003A1 (en) | 2018-07-04 |
JP6921894B2 (ja) | 2021-08-18 |
JP2017520628A (ja) | 2017-07-27 |
EA039069B1 (ru) | 2021-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018502251A1 (en) | Formulations of an lsd1 inhibitor | |
PL3577135T3 (pl) | Kompozycja farmaceutyczna do stosowania do leczenia lub zapobiegania chorobom związanym z c5 | |
PH12016501830A1 (en) | Inhibitors of c5a for the treatment of viral pneumonia | |
MA39710A (fr) | Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin | |
MX2017002816A (es) | Derivados de pirazolopiridina y su uso en terapia. | |
IL273125A (en) | Pharmaceutical formulations of cyclic oligomer of abiraterone and methods of making and taking them | |
PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
MX2016014859A (es) | Composiciones farmaceuticas que comprenden danirixina para tratar enfermedades infecciosas. | |
PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
MX2017001461A (es) | Terapia de combinacion. | |
IL251687B (en) | Medicinal composition for use in treatment to prevent vitamin and mineral deficiencies in patients who have undergone gastric bypass surgery | |
IN2014DN09240A (es) | ||
PH12019501820A1 (en) | Pharmaceutical compositions for combination therapy | |
MX2017000399A (es) | Tableta dispersable de misoprostol. | |
JO3321B1 (ar) | قرص قابل للتشتت من ميزوبروستول | |
IL257689B (en) | Pharmaceutical preparations and methods for treating diseases related to lack of oxygen | |
MX2018015240A (es) | Composiciones que comprenden timolol y su uso en el tratamiento de rosacea mediante administracion topica. | |
NZ739679A (en) | Cholecalciferol sulfate salts and their use for the treatment of vitamin d deficiency | |
MX2018003564A (es) | 1,4-benzodiazepinas biheteroarilo sustituidas y usos de las mismas para el tratamiento del cancer. | |
WO2016083315A8 (en) | Use of ox1r antagonists for the treatment of inflammatory bowel diseases | |
TH167850B (th) | (r)-เพอร์ลินโดล และเกลือที่ยอมรับได้ทางเภสัชกรรมของมันสำหรับการใช้ ในยารักษาโรค |